The Business Times
business-time-50

Merck

International

Merck to create separate cancer business as Keytruda patent loss looms

2026-02-23T14:57:37.000Z
Merck plans to reduce its global real estate footprint and optimise its manufacturing network.
Consumer & Healthcare

Merck to cut jobs and costs as demand for Gardasil in China remains weak

2025-07-29T10:48:31.000Z
Merck’s acquisition would fast track the international launch of the drug in countries outside the US.
Consumer & Healthcare

Merck nears US$10 billion deal for London-based lung therapy firm Verona, FT reports

2025-07-09T09:36:46.000Z
Merck submitted a nonbinding offer for MoonLake Immunotherapeutics earlier this year, according to the report, which added that the initial approach was rejected but talks could be revived.
Companies & Markets

Merck held talks to buy biotech MoonLake for over US$3 billion: FT

2025-06-02T23:45:23.000Z
Merck can now integrate vaccine production within its own manufacturing network to supply global markets.
Consumer & Healthcare

China’s WuXi Biologics to sell vaccine facility to Merck for US$500 million

2025-01-07T03:51:29.000Z
Drugmakers have been racing to come up with pills that could duplicate the effects of Ozempic but would be more convenient to take.
Consumer & Healthcare

Merck snags Chinese obesity drug in nearly US$2 billion deal

2024-12-19T00:01:07.000Z
The deal with LaNova Medicines bolsters Merck’s push into the promising new field of dual-targeted antibodies.
Consumer & Healthcare

Merck snags Chinese cancer drug for up to US$3.3 billion

2024-11-14T14:50:00.000Z
Merck now expects total sales of up to US$64.1 billion for the year, US$300 million less than the top end of the guidance the company provided three months ago.
Consumer & Healthcare

Merck narrows sales outlook with Gardasil lagging in China

2024-10-31T15:12:32.000Z
Merck narrowed expectations for its Life Science business, aiming for annual organic sales growth in a 7-to-9 per cent range from a previously anticipated 7 to 10 per cent.
Consumer & Healthcare

Germany’s Merck open to more M&A for its Life Science division

2024-10-17T08:37:25.000Z
Merck posted a profit of US$5.5 billion, or US$2.14 per share for its second-quarter results on strong growth of its blockbuster cancer immunotherapy Keytruda.
Companies & Markets

Merck cuts annual profit forecast

2024-07-30T11:27:14.000Z
Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More